OncoCyte, Wistar to Develop Gene Expression-based Lung Cancer Diagnostic | GenomeWeb

NEW YORK (GenomeWeb News) – BioTime subsidiary OncoCyte today announced that it will collaborate with the Wistar Institute on the development of a gene expression-based lung cancer test.

Under the agreement, OncoCyte scientists will use the firm's cancer diagnostic test, PanC-Dx, to analyze levels of tumor-associated proteins in blood samples from patients in an ongoing study conducted by Wistar. Scheduled to wrap up in mid-2104, two thirds of the planned total of 600 samples have already been collected in the study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.